1. Research, Mobility and commercialisation:
ERA-MIND meeting on Mobility
Key issues in investing in People
Trieste, Italy, May 2010
Dr Frank Heemskerk, RIMS bvba; Brussels 26 Febr09

2. About a presenter… Frank Heemskerk
Academic research (15 yr):
Biomedical: Neuroscience
HOW does it work?
Can we apply this to better
therapies?
Utrecht (NL)
Nat’l Inst Health (USA)
UPasteur (FR)
But no tenure position...
many different grants and working
with industrial partners ☺
Personal -international- network !
=>Joint decisions to move: dual
careers !
Dr Frank Heemskerk, RIMS bvba; Brussels 26 Febr09 2

3. About a presenter… Frank Heemskerk
Industry experience (13 yr):
Biotech/pharma, Research
Management, contracts, IPR, licensing,
partnerships with academia, merger,
multiple private investments
Moving to Belgium and into Industry
How can we use joint knowledge to
develop better therapies?
International Research Management:
Biotech/Pharma, past-President EARMA
RIMS bvba founder (2002), board
member of several small companies
Developing global networks (2500)
How can we manage consortia?
Develop and grow companies?
Create socio-economic value together?
Dr Frank Heemskerk, RIMS bvba; Brussels 26 Febr09 3

4. Hard Skills: Soft Skills:
- scientific/technical knowledge across
- Networking !
disciplines
- Teamwork
- Project management
- Presentation skills !
- Time management
- Empathy
- Budgeting
- negotiation skills
Dr Frank Heemskerk, RIMS bvba; Brussels 26 Febr09 4

5. Possible barriers for discussion:
1) personal level:
Level of contacts: role of networks
skill base: can be developed over time
Family situation: dual careers, childres, etc
2) collaboration level:
Is industry partner open for hosting?
Strutcure of cooperation agreement (IPR, financial transfer,
retention, long or short term contracts, one-one or network)
Responsible partnering Guidelines, workshops, etc
3) national level:
legal, financial/ tax and Social security
Role of support/ service centres, job portals/ information
services
PR on role models in media and schools
Allow flexibility in assignments (business people in education...?)
Dr Frank Heemskerk, RIMS bvba; Brussels 26 Febr09 5

6. Recommendations for discussion:
1) e.g. Medicine vs Biotech, Chemistry - bad image, but
we use products everyday =>PR actions, education,
media => Visibility and basic understanding
2) multi-diciplinary teamwork, exchange with industry,
projects, interactions between schools and industry !
3) Help those who want to take initiative:
Helpdesks, mentoring schemes, portals
PR on role models in media and schools
Stimulate networks, associations to help overcome barriers
Flexible working conditions
Dr Frank Heemskerk, RIMS bvba; Brussels 26 Febr09 6

7. Examples from practise
Sharing goodpractices: successful
interaction experiences between
industry and academia
Dr Frank Heemskerk, RIMS bvba; Brussels 26 Febr09 7

8. WHY invest in R&D SMEs?
Where is the Value in joint R&D projects?
Innovate products and processes
Feed pipeline with new/ improved products
Diversify portfolio
Why invest now?: // current economic climate
Access to new knowledge, unique infrastructure, valuable materials,
information dbases
Achieve critical mass (work faster/disseminate wider/ increase visibility)
new experts (future staff?)
• Often SMEs drive innovation (products, services,
new or niche markets)
• quite SMEs can be more flexible// react faster
• Attract more public funding to lower risk
Dr Frank Heemskerk, RIMS bvba; Brussels 26 Febr09 8

9. Main Objectives: what do you want?
What do you want to achieve?
Innovate products and processes
Feed pipeline with new/ improved products
Diversify portfolio
Enter new markets
enhance visibility
What do you want to avoid?:
Loose competitive advantage (is always temporary !)
loose key knowledge
Loose key experts
old infrastructure
Work in isolation (influencing power)
…
Dr Frank Heemskerk, RIMS bvba; Brussels 26 Febr09 9

10. Project Management and Value chain
Dr Frank Heemskerk, RIMS bvba; Brussels 26 Febr09 10

11. “Due to the proliferation of information in the discovery
space, the new R&D business model will evolve to virtual
networks of coordinated service providers”
Genome Information Network Contract Discovery
Toxicogenomics DBs Functional
Predictive Modeling HTS and
Genomics
and Rational Design Combi-Chem
DBs
Population
Metabonomics
Genomics DBs Novel Biologics
DBs Bioinformatics
Target Design
ID
Formulation & Hardware
Manufacturing Regula- Lead Infrastructure
B2B Reagent Exchange tory Virtual R&D Discovery
Hardware/ASP
Formulation Network
Clinical Privacy and
Valid.
Security
Automated
Chemical Clinical Validation Dri-Science Technology Data Management
Synthesis Patient
Protocol Planning &
Recruitment Bioinformatics Chemi-
Management
informatics
Global Diagnostics &
Submission Predictive Modeling
Monitoring
Source: Accenture Analysis, 2001
Dr Frank Heemskerk, RIMS bvba; Brussels 26 Febr09 11

12. Transfer of knowledge: from academia to...:
Academic Consulting, contract
research
Exchange Graduate students
Exchange of staff/ faculty
Collaborative Research projects
Patenting and licensing Spin-off
companies (JV, PPP, etc)
Service and out-reach
Networking (critical mass)
Policy recommendations
Dr Frank Heemskerk, RIMS bvba; Brussels 26 Febr09 12

13. Transfer of knowledge:
- Ownership (who owns what) ?
- Background/Foreground ?
- Individual/ Institutional inventorship
- (sub)contractor vs partner ?
- Acces rights vs User Rights vs Commercialization ?
- Co-development?
- Financial Conditions (upfront, milestones, IP costs, royalty
structure) ?
- Partners will have varied levels of experience and
expertise in Research management/ Knowledge
Transfer practices
- Gaps between academics, entrepreneurs and investors:
impact on collaborations, practices, need for training,
professionalism
- International differences: financial, cultural and legal
frameworks differ
Dr Frank Heemskerk, RIMS bvba; Brussels 26 Febr09 13

14. The Innovation Value chain:
Risk perception and your Role
Research Development Market
Validate Prototypes Industrialize
Technol-Commercial Cash needs
Value
Perceived Risk
Parallel Product Development
& Transfer at right moment
Seed, BA,FFF Local VC Int’l VC IPO Funding
Dr Frank Heemskerk, RIMS bvba; Brussels 26 Febr09 14

15. rest of Society/
regulatory
Government:
ethical
legal
Academia fiscal
infrastructure
understanding education!
cooperation
exchange
Understanding
matching
Industry Investors
expectations
Dr Frank Heemskerk, RIMS bvba; Brussels 26 Febr09 15

16. Knowledge triangle (FP7)
•Added value of an international network (new ideas)
•Added value of international exploitation (new applications, mobility)
•Critical mass (to fight fragmentation in Europe)
Knowledge for Growth
Research
Open Innovation,
Mobility
Innov in Educ,
new ideas skilled people,
Services, products
skilled people
Knowledge, concepts
Education Innovation
New multidiscipl. challenges
Dr Frank Heemskerk, RIMS bvba; Brussels 26 Febr09 16

17. Academia-Industry: Challenges
1. Communication!
2. Differences in management culture
3. Partners will have varied levels of experience and
expertise in Research management/ Knowledge
Transfer practices
4. Different timelines (days, years) and expectations (%, €)
5. Lack of insight in business development
6. Insufficient capacity (€, investment)
7. Organizational capacity
PLUS: beware of International differences: financial,
cultural and legal frameworks differ
Dr Frank Heemskerk, RIMS bvba; Brussels 26 Febr09 17

18. “Increasingly international R&D is done in a
complex network environment: you need research
management professionals to enable the different
players to act together”
Dr Frank Heemskerk, RIMS bvba; Brussels 26 Febr09 18

19. Project example:
M Curie Mobility project in chemical catalysis:
Match 2 different academic groups in 2 countries + 1 SME
Idea 1 => invite 2 Fellows from across Europe to acquire knowledge for
one year at both Universities + 1 fellow for research program in SME
Idea 2 => in second stage swap places: industrial fellow goes to academia
and 2 academic fellows go to SME
VALUE:
Consortium to do Research + Development in parallel
Matching expertise of 2 different academic fields with industrial
requirements
Unique transfer of knowledge across borders and sectors
Center of excellence for a very focused field with valuable industrial
applications
High level training events in specialist area
Possibly company growth (jobs) and leverage for investment (more €)
Dr Frank Heemskerk, RIMS bvba; Brussels 26 Febr09 19

20. example Mexico-Europe cooperation: 1
large prenatal Diagnostics project: 20weeks 12w screening
8 Hospitals : SP (2), BE,
SLO, GK, CH, MEX
Research Institutes: UK (2) No Preventive
Prevention Interventions
3 SMEs: SP, BE and MEX
4 years, 6 M€
Problem: 1.8 million neonatal deaths/year, no early detection method;
rate in MEX= 10x EU
Objectives:
develop diagnostic test (proteomics) and tools (biomarkers) to detect
high risk for miscarriage
validate in clinical studies in Mexico
Transfer knwoledge to Mexico for diagnostic business in LA
Dr Frank Heemskerk, RIMS bvba; Brussels 26 Febr09 20

21. example Mexico-Europe cooperation: 2
Large Biofuel project:
Universities: NL, AT, MEX
Research Institutes: MEX (2), SAfr, Moz
SMEs: BE, MEX, NL (3)
3 years, 3.6 M€
Problem: Biofuel from food not sustainable, Mexican Jatropha palms
can deliver high yield, but need to be optimized
Objectives:
select best species (from >300) and characterize (genomics,
proteomics)
Develop cultivation methods and
Optimize oil extraction methods and other side products
create business case
knowledge transfer between Europe, Mexico and Africa
Dr Frank Heemskerk, RIMS bvba; Brussels 26 Febr09 21

22. Cluster example:
Small M Curie Chair project:
Top female specialist USA => Central European country
Idea => Chair at University + research program on HIV vaccine
(Nanomedicine)
VALUE coming out:
Develop larger Consortium to do world class R&D
Develop a Clinical trials vaccine cluster: building up specific
expertise
Center of excellence that is unique for Central-East Europe
High level training events in specialist areas
Now a spin-off company (jobs) + leverage for investment (private €)
Dr Frank Heemskerk, RIMS bvba; Brussels 26 Febr09 22

23. Cluster Strategic Product Development Plan:
New ideas pipeline
Transfer to others
Test with patients: safety+efficacy
Build prototypes
© VTC ImmuneTherapy cluster
Dr Frank Heemskerk, RIMS bvba; Brussels 26 Febr09 23

24. Company example: Flemish region of Belgium
Create leverage (industry case):
Idea for proprietary HIV assay => patent + specific know how +
unique proprietary dbase
1. Enables faster drug discovery progam (core) => attract investment
1 for drug development (Tibotec)
2. Enables Spin-off company for diagnostics=> short term revenue
stream (Virco)
3. Enables to attract investment 2 for capacity development =>
result: Real GROWTH
• Tibotec (started 1994) - Virco (started 1995)
• 1998: 28 people
• 2002: 250 people and acquired by Johnson& Johnson (500 M€)
• 2009: 650 people and 2 drugs on the market
Dr Frank Heemskerk, RIMS bvba; Brussels 26 Febr09 24

25. Understanding HIV Drug resistance is the key
to new drugs
Platforms
Treatment
Genomics monitoring
UHTS tools
Phenotyping
Bioinformatics
Phenotypic Genotypic
Database Database
Pharmacogenomics engine
Drug
Targets
New Drugs
Drug
Discovery & Development
Dr Frank Heemskerk, RIMS bvba; Brussels 26 Febr09 25

26. Research Development Innovation
Services
Suppliers
Products
Knowledge
Shorter time to market
Experienced management access to new markets
Strategy building Sufficient private funding Sufficient capacity
Consortium building
and public funding Expert partners Risk control
Dr Frank Heemskerk, RIMS bvba; Brussels 26 Febr09 26

27. Thank you for your attention.
Further information:
Research & Innovation
Management Services bvba
Dr Frank Heemskerk
E= Frank.Heemskerk@telenet.be
T= +32 16 474092
www.rimsinternational.eu
Dr Frank Heemskerk, RIMS bvba; Brussels 26 Febr09 27

28. Recommendations:
1. Set internal rules (management decisions, IPR, communication,
finance, infrastructure, publications, ...)
2. Create an environment open for collaboration
3. Allow a variety of funding streams
4. Think in processes: (R=>D=>solutions=>more R, etc)
Research Mgngmt and Knowledge Transfer offices,
but also professionalize support staff, students, etc
5. Communicate effectively to different stakeholders!
6. Innovate the Evaluation of staff, projects, outcomes: not just on #
publications, but also on patents, quality of partnerships, socio-
economic outcomes, risk, retention of key assets, etc
Dr Frank Heemskerk, RIMS bvba; Brussels 26 Febr09 28